Clinical trial NCT05729269: Characterization of Gut Microbiota in Chronic Liver Disease With Decreased Muscle Mass
Official title: Characterization of Gut Microbiota in Chronic Liver Disease With Decreased Muscle Mass
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gastrointestinal Microbiome
Sarcopenia
Liver Disease Chronic
Lead sponsor: Chuncheon Sacred Heart Hospital
Sponsor class: OTHER
Collaborators: name: Dongtan Sacred Heart Hospital
name: Hallym University Medical Center
name: Hangang Sacred Heart Hospital
name: Kangdong Sacred Heart Hospital
name: Yonsei University
First posted: 2023-02-15
Enrollment: 283
Sex: ALL
Minimum age (years): 24
Maximum age (years): 82
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: From January 2017 to December 2019, 489 patients who agreed to collect feces among the cohort patients with chronic liver disease in five hospitals under the Hallym University Medical Center were surveyed.

Brief summary: The purpose of this study was to confirm the presence of specific gut microbiota observed in patients with sarcopenia among patients who agreed to analyze gut microbiota through stool among multi-center chronic liver disease cohort patients.

Detailed description: The effect of gut microbiota on liver disease is also well known and many studies are ongoing. A recently published study summarized the differences in the composition of gut microbiota in non-alcoholic fatty liver, steatohepatitis, and cirrhosis, and reported that metabolites from the changed gut microbiota may be a factor influencing non-alcoholic fatty liver disease (NAFLD) progression. These changes in gut microbiota composition have been reported to affect clinical outcomes in patients by causing an increase in endotoxin, a change in bile acid metabolism, and a decrease in short chain fatty acid. In particular, the reduction of short chain fatty acid is known to be associated with the occurrence of sarcopenia. Sarcopenia, which is common in patients with cirrhosis, which is a representative chronic liver disease, is well known as a poor prognostic factor for patients. Therefore, this study aims to analyze the distribution of gut microbiota observed in patients with sarcopenia through the gut microbiota investigated in the chronic liver disease cohort patient group and the characteristics of the distribution of gut microbiota for each disease corresponding to chronic liver disease.

Eligibility criteria: Inclusion Criteria:

* 1. Patients who have chronic liver disease (chronic liver disease cohort): alcohol liver disease, non-alcoholic liver disease, liver cirrhosis 2. Patients who consented to a study confirming the gut microbiota 3. Patients with abdominal computed tomography scan taken one month before or after submitting stool for gut microbiota analysis

Exclusion Criteria:

* Patients whose height and weight records are missing from the chart review

Primary outcomes:
measure: Fecal gut microbiota between sarcopenia group and non-sarcopenia group
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Chuncheon
country: Korea, Republic of
facility: Department of Internal Medicine, Hallym University Medical College
state: Gangwon-do
Study officials:
References: